Valuation : Jasper Therapeutics, Inc.

Market Cap 21.97M 18.96M 17.95M 16.25M 30.47M 2.1B 30.7M 213M 81.89M 1.07B 82.48M 80.69M 3.38B P/E 2026 *
-0.99x
P/E 2027 * -0.59x
Enterprise Value -127M -110M -104M -94.1M -176M -12.16B -178M -1.23B -474M -6.18B -478M -467M -19.55B EV / Sales 2026 *
-53x
EV / Sales 2027 * -
Free-Float
97.13%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Jasper Therapeutics, Inc.

1 day-5.77%
1 week-6.82%
Current month-7.18%
1 month-23.50%
3 months+44.30%
6 months-45.88%
Current year-63.92%
1 week 0.66
Extreme 0.66
0.74
1 month 0.63
Extreme 0.6346
0.92
Current year 0.32
Extreme 0.3151
2.07
1 year 0.32
Extreme 0.3151
2.69
3 years 0.32
Extreme 0.3151
31.01
5 years 0.32
Extreme 0.3151
188.8
10 years 0.32
Extreme 0.3151
188.8
Manager TitleAgeSince
Chief Executive Officer 54 2026-01-05
Director of Finance/CFO 54 2023-09-21
Chief Operating Officer 59 2026-07-15
Director TitleAgeSince
Chairman 74 2023-10-31
Director/Board Member 58 2021-09-23
Director/Board Member 54 2026-01-05
Date Insider Type Main position Quantity % Market Cap. Importance
7/31/26 Free

Founder

7,500 0.0267%
7/31/26 Free

Director

7,500 0.0267%
7/31/26 Free

Chairman

7,500 0.0267%
Change 5-day change 1-year change 3-year change Capi.($)
-5.77%-6.82%-72.83%-91.19% 21.97M
-2.11%-1.68%+43.40%+95.27% 66.93B
-0.23%-4.45%+32.50%+77.58% 61.97B
+1.67%+2.47%-11.32%+392.05% 28.26B
-1.05%-4.43%+28.84%+10.59% 24.59B
+0.34%-6.78%-0.01%-14.59% 24.3B
+0.43%-3.37%+16.22%-17.99% 19.41B
-3.03%-2.29%+181.72%+335.27% 16.77B
-1.94%-4.94%-8.15%+483.69% 14.18B
+3.24%-0.31%-7.34%+833.51% 14B
Average -0.84%-3.33%+20.30%+210.42% 27.04B
Weighted average by Cap. -0.56%-2.83%+31.25%+169.98%

Financials

2026 *2027 *
Net sales 2.4M 2.07M 1.96M 1.78M 3.33M 229M 3.35M 23.25M 8.94M 117M 9.01M 8.81M 369M -
Net income -19.7M -17M -16.1M -14.57M -27.32M -1.88B -27.52M -191M -73.42M -957M -73.95M -72.35M -3.03B -57.36M -49.5M -46.87M -42.42M -79.56M -5.48B -80.14M -556M -214M -2.79B -215M -211M -8.81B
Net Debt -149M -129M -122M -110M -207M -14.25B -208M -1.45B -556M -7.25B -560M -548M -22.93B -310M -268M -253M -229M -430M -29.62B -433M -3B -1.16B -15.07B -1.16B -1.14B -47.65B
Logo Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. Its lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the c-Kit receptor, inhibiting signaling for mast cells and a maintenance signal for hematopoietic stem cells. KIT inhibition with briquilimab has demonstrated clinical outcomes both as a conditioning agent for stem cell transplant in SCID and Fanconi anemia. Its pipeline also includes KP-104 (vensobafusp alfa), a bifunctional complement inhibitor in clinical development, and KP-701, a preclinical B-cell receptor-targeted therapy.
Employees
22
Date Price Change Volume
26-09-11 US$0.6603 -5.77% 294,293
26-09-10 US$0.7007 -0.04% 208,007
26-09-09 US$0.7010 -1.18% 60,346
26-09-08 US$0.7094 +0.11% 189,959
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
0.6603USD
Average target price
7.375USD
Spread / Average Target
+1,016.92%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JSPR Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!